Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team, including President and CEO Seth Lederman, M.D., will participate in one-on-one meetings at BTIG's Infectious Disease Day 2026, to be held virtually on June 16, 2026. The event provides a platform for Tonix to showcase its immunology pipeline, which includes candidates targeting infectious diseases and immune-mediated conditions.
Tonix is a fully integrated commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), recently became the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra.
Beyond its CNS portfolio, Tonix is advancing a pipeline of immunology programs. Notably, TNX-4800 is a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500 is a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These candidates underscore Tonix's expansion into infectious disease and immunology, areas of significant unmet need and market potential.
The BTIG Infectious Disease Day 2026 offers Tonix an opportunity to engage with investors and industry experts, potentially increasing visibility for its immunology assets. For leaders in business and technology, this participation signals Tonix's strategic focus on broadening its therapeutic reach beyond CNS disorders. The company's efforts in Lyme disease prophylaxis are particularly relevant given the rising incidence of tick-borne diseases, while TNX-1500 addresses a critical need in transplant medicine.
Tonix's involvement in this event may influence investor sentiment and highlight the company's dual focus on CNS and immunology. As the biotechnology sector continues to evolve, Tonix's diversified pipeline could position it for growth across multiple therapeutic areas. The virtual nature of the event ensures broad accessibility, allowing stakeholders to gain insights into Tonix's progress and future direction.
For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/38XUG.
